Secondary malignant neoplasms · Patients with untreated Hodgkin lymphoma (early and advanced stages)
Chemotherapy alone may leads to lower secondary malignant neoplasms compared with same chemotherapy plus radiotherapy (low certainty).
1 finding from 1 review
Secondary malignant neoplasms · Patients with untreated Hodgkin lymphoma (early stages)
Fewer showed no clear difference in secondary malignant neoplasms compared with more courses of chemotherapy (with or without radiotherapy (moderate certainty).
1 finding from 1 review
Death · Patients with untreated Hodgkin lymphoma (early stages)
Fewer showed no clear difference in death compared with more courses of chemotherapy (with or without radiotherapy (high certainty).
1 finding from 1 review
Progression/relapse · Patients with untreated Hodgkin lymphoma (early stages)
Fewer showed no clear difference in progression/relapse compared with more courses of chemotherapy (with or without radiotherapy (high certainty).
1 finding from 1 review
Secondary malignant neoplasms · Patients with untreated Hodgkin lymphoma (advanced stages)
Dose‐intensified chemotherapy showed no clear difference in secondary malignant neoplasms compared with ABVD‐like chemotherapy (with or without radiotherapy (low certainty).
1 finding from 1 review
Death · Patients with untreated Hodgkin lymphoma (advanced stages)
Dose‐intensified chemotherapy showed no clear difference in death compared with ABVD‐like chemotherapy (with or without radiotherapy (moderate certainty).
1 finding from 1 review
Progression/relapse · Patients with untreated Hodgkin lymphoma (advanced stages)
Dose‐intensified chemotherapy probably leads to lower progression/relapse compared with ABVD‐like chemotherapy (with or without radiotherapy (moderate certainty).
1 finding from 1 review
Death · Patients with untreated Hodgkin lymphoma (early and advanced stages)
Chemotherapy alone showed no clear difference in death compared with same chemotherapy plus radiotherapy (moderate certainty).
1 finding from 1 review
Progression/relapse · Patients with untreated Hodgkin lymphoma (early and advanced stages)
Chemotherapy alone showed no clear difference in progression/relapse compared with same chemotherapy plus radiotherapy (moderate certainty).
1 finding from 1 review
Local recurrence · breast‐conserving radiotherapy for breast cancer
Boost may leads to lower local control: recurrence at 5 years compared with no boost (low certainty).
1 finding from 1 review
Overall survival: mortality at 5 years · breast‐conserving radiotherapy for breast cancer
Boost showed no clear difference in overall survival: mortality at 5 years compared with no boost (moderate certainty).
1 finding from 1 review
Disease-free survival (new disease, progression or mortality) · breast‐conserving radiotherapy for breast cancer
Boost showed no clear difference in disease‐free survival: disease progression/mortality at 5 years compared with no boost (low certainty).
1 finding from 1 review
Late toxicity, pBRA · breast‐conserving radiotherapy for breast cancer
It is very uncertain whether boost changes late toxicity, pBRA compared with no boost (very low certainty).
1 finding from 1 review
Cosmesis · breast‐conserving radiotherapy for breast cancer
Boost may leads to higher cosmesis, panel scored: fair or poor compared with no boost (low certainty).
2 findings from 1 review
Sensitivity analysis: local control ‐ recurrence at 5 years · breast‐conserving radiotherapy for breast cancer
Boost leads to lower sensitivity analysis: local control ‐ recurrence at 5 years compared with no boost (high certainty).
1 finding from 1 review
Subgroup analysis: local control ‐ > 40 years old, recurrence at 5 years · breast‐conserving radiotherapy for breast cancer
Boost leads to lower subgroup analysis: local control ‐ > 40 years old, recurrence at 5… compared with no boost (high certainty).
1 finding from 1 review
Nausea · participants with advanced cancer who have nausea and vomiting not related to chemotherapy, radiotherapy, or surgery
1 finding from 1 review
Number of vomiting episodes · participants with advanced cancer who have nausea and vomiting not related to chemotherapy, radiotherapy, or surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · participants with advanced cancer who have nausea and vomiting not related to chemotherapy, radiotherapy, or surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · participants with advanced cancer who have nausea and vomiting not related to chemotherapy, radiotherapy, or surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found